Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Letrozole × Breast × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 372 Neoplasm Metastasis 19 Neoplasms 11 Advanced Breast Cancer 10 Carcinoma, Intraductal, Noninfiltrating 8 Osteoporosis 7 Carcinoma, Ductal, Breast 7 Breast Neoplasms, Male 7 Breast Diseases 7 Triple Negative Breast Neoplasms 6 Breast Carcinoma In Situ 6 Carcinoma, Lobular 5 Hereditary Sensory and Autonomic Neuropathies 4 Breast Cancer Metastatic 4 Arthralgia 4 Recurrence 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasms, Hormone-Dependent 3 Squamous Cell Carcinoma of Head and Neck 2 Pain 2 Obesity 2 Neoplasms by Site 2 Multiple Endocrine Neoplasia Type 1 2 Infertility 2 Head and Neck Neoplasms 2 HR+/HER2- Breast Cancer 2 HR Positive HER2 Negative Advanced Breast Cancer 2 Estrogen Receptor-positive Breast Cancer 2 Endometrial Neoplasms 2

Interventions

palbociclib 2 Trastuzumab 2 Capecitabine 2 trastuzumab deruxtecan 1 tetrathiomolybdate 1 sacituzumab govitecan 1 pembrolizumab 1 niraparib 1 inavolisib 1 giredestrant 1 eribulin 1 avelumab 1 atezolizumab 1 abemaciclib 1 Zymosan 1 Radiotherapy 1 Letrozole 1 Immunotherapy 1 Hydroxychloroquine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04130152 2022-10-25

PROMETEO II

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡